Close Icon

Remote Monitoring

What’s critical during a pandemic is good clinical practice all the time.

New FDA guidance recommends remote monitoring to maintain oversight of clinical sites during the COVID-19 pandemic. This dovetails with earlier guidance, updated in 2016, on the importance of these capabilities to help detect data anomalies in real time and quickly correct any identified deficiencies.

What’s more, limiting travel expenses and reducing reliance on manual processes makes good business sense no matter what the conditions are on the ground.

While Saama offers a complete Risk-Based Monitoring solution, in the short term we can get you up and running fast with Remote Monitoring of your EDC and CTMS data.

Drive Workflow Efficiency—Now and into the Future

By working quickly to leverage technology, you’ll be able to preserve the integrity of your clinical trials.

Get Started Today

For more information on how Remote Monitoring can help ensure study continuity—during and after the COVID-19 outbreak—contact us.

Remote Monitoring Benefits at a Glance

  • Maintain current pace of the study
  • Preserve the scientific integrity of the trial
  • Preserve the value of CRA interaction with sites and sponsors
  • Reduce regulatory and compliance risk

Our Remote Monitoring solution is designed for your convenience

One-Click Drilldown

Investigate data at every level: portfolio, site, and study.

Selective Filters

Use filters to isolate and analyze specific areas of concern.

Tasks & Workflows

Automate task generation and follow up.

Audit Trails

Ensure compliance and audit readiness with centralized documentation of issues, actions, and resolution.

Risk Analysis

View key performance trends in a near real-time environment.

Terms & Conditions

By inquiring about Saama’s Database Lock in a Day, you agree to be contacted by Saama and to allow Saama to use, maintain, store, and protect your personal data in accordance with our Privacy Policy.

Eligibility details are for informational purposes only. Saama, in its sole discretion, will determine your eligibility based on the information you disclose as part of the intake process. If Saama determines that you are eligible to participate, you will be notified by separate email. Eligibility depends on certain criteria, such as the size of your company, the types of clinical trials you sponsor, and the number of patients in–and stages of–your current clinical trials.

By completing the request form, you represent that you have authority to proceed on behalf of your company. Should you agree to participate, you agree to reasonably cooperate with Saama in following the guidelines and procedures required for integrating, standardizing, and analyzing your data. Participation requires the use of our Smart Data Quality application, a technology-agnostic AI engine that sits on top of your current infrastructure. The application can be used immediately, and you’re only charged for the services you use based on a predetermined estimate.

Information you share with Saama during your participation may be anonymized and/or aggregated, and made available publicly in Saama marketing materials. This information may include: types of systems and processes involved, types of departments involved, and size and regional location of your company. Such information will never be directly associated with you, nor will you or your company be identifiable without express written permission.